Literature DB >> 12651161

Roles of mitogen-activated protein kinase and phosphoinositide 3'-kinase in ErbB2/ErbB3 coreceptor-mediated heregulin signaling.

Ulka Vijapurkar1, Myong-Soo Kim, John G Koland.   

Abstract

ErbB2/HER2 and ErbB3/HER3, two members of the ErbB/HER family, together constitute a heregulin coreceptor complex that elicits a potent mitogenic and transforming signal. Among known intracellular effectors of the ErbB2/ErbB3 heregulin coreceptor are mitogen-activated protein kinase (MAPK) and phosphoinositide (PI) 3-kinase. Activation of the distinct MAPK and PI 3-kinase signaling pathways by the ErbB2/ErbB3 coreceptor in response to heregulin and their relative contributions to the mitogenic and transformation potentials of the activated coreceptor were investigated here. To this end, cDNAs encoding the wild-type ErbB3 protein (ErbB3-WT) and ErbB3 proteins with amino acid substitutions in either the Shc-binding site (ErbB3-Y1325F), the six putative PI 3-kinase-binding sites (ErbB3-6F), or both (ErbB3-7F) were generated and expressed in NIH-3T3 cells to form functional ErbB2/ErbB3 heregulin coreceptors. While the coreceptor incorporating ErbB3-WT activated both the MAPK and the PI 3-kinase signaling pathways, those incorporating ErbB3-Y1325F or ErbB3-6F activated either PI 3-kinase or MAPK, respectively. The ErbB2/ErbB3-7F coreceptor activated neither. Elimination of either signaling pathway lowered basal and eliminated heregulin-dependent expression of cyclin D1, which was in each case accompanied by an attenuated mitogenic response. Selective elimination of the PI 3-kinase pathway severely impaired the ability of heregulin to transform cells expressing the coreceptor, whereas attenuation of the MAPK pathway had a lesser effect. Thus, while both pathways contributed in a roughly additive manner to the mitogenic response elicited by the activated ErbB2/ErbB3 coreceptor, the PI 3-kinase pathway predominated in the induction of cellular transformation.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12651161     DOI: 10.1016/s0014-4827(02)00040-x

Source DB:  PubMed          Journal:  Exp Cell Res        ISSN: 0014-4827            Impact factor:   3.905


  20 in total

1.  Increased expression of MyD88 and association with paclitaxel resistance in breast cancer.

Authors:  Fenfen Xiang; Zhenhua Ni; Yueping Zhan; Qianqian Kong; Jian Xu; Jiemin Jiang; Rong Wu; Xiangdong Kang
Journal:  Tumour Biol       Date:  2015-11-23

2.  Zinc finger transcription factors designed for bispecific coregulation of ErbB2 and ErbB3 receptors: insights into ErbB receptor biology.

Authors:  Caren V Lund; Mikhail Popkov; Laurent Magnenat; Carlos F Barbas
Journal:  Mol Cell Biol       Date:  2005-10       Impact factor: 4.272

3.  PTEN Loss Is Associated with Worse Outcome in HER2-Amplified Breast Cancer Patients but Is Not Associated with Trastuzumab Resistance.

Authors:  Howard M Stern; Humphrey Gardner; Tomasz Burzykowski; Wafaa Elatre; Carol O'Brien; Mark R Lackner; Gary A Pestano; Angela Santiago; Ivonne Villalobos; Wolfgang Eiermann; Tadeusz Pienkowski; Miguel Martin; Nicholas Robert; John Crown; Paolo Nuciforo; Valerie Bee; John Mackey; Dennis J Slamon; Michael F Press
Journal:  Clin Cancer Res       Date:  2015-02-03       Impact factor: 12.531

4.  Essential role for Rac in heregulin beta1 mitogenic signaling: a mechanism that involves epidermal growth factor receptor and is independent of ErbB4.

Authors:  Chengfeng Yang; Ying Liu; Mark A Lemmon; Marcelo G Kazanietz
Journal:  Mol Cell Biol       Date:  2006-02       Impact factor: 4.272

5.  Endothelial Jarid2/Jumonji is required for normal cardiac development and proper Notch1 expression.

Authors:  Matthew R Mysliwiec; Emery H Bresnick; Youngsook Lee
Journal:  J Biol Chem       Date:  2011-03-14       Impact factor: 5.157

Review 6.  Roles for neuregulins in human cancer.

Authors:  Christophe Stove; Marc Bracke
Journal:  Clin Exp Metastasis       Date:  2004       Impact factor: 5.150

Review 7.  The oncogene HER2: its signaling and transforming functions and its role in human cancer pathogenesis.

Authors:  M M Moasser
Journal:  Oncogene       Date:  2007-04-30       Impact factor: 9.867

8.  Transforming growth factor beta engages TACE and ErbB3 to activate phosphatidylinositol-3 kinase/Akt in ErbB2-overexpressing breast cancer and desensitizes cells to trastuzumab.

Authors:  Shizhen Emily Wang; Bin Xiang; Marta Guix; Maria Graciela Olivares; Joel Parker; Christine H Chung; Atanasio Pandiella; Carlos L Arteaga
Journal:  Mol Cell Biol       Date:  2008-07-14       Impact factor: 4.272

Review 9.  The ERBB3 receptor in cancer and cancer gene therapy.

Authors:  G Sithanandam; L M Anderson
Journal:  Cancer Gene Ther       Date:  2008-04-11       Impact factor: 5.987

10.  The Metastasis Suppressor, N-MYC Downstream-regulated Gene-1 (NDRG1), Down-regulates the ErbB Family of Receptors to Inhibit Downstream Oncogenic Signaling Pathways.

Authors:  Zaklina Kovacevic; Sharleen V Menezes; Sumit Sahni; Danuta S Kalinowski; Dong-Hun Bae; Darius J R Lane; Des R Richardson
Journal:  J Biol Chem       Date:  2015-11-03       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.